Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ranbaxy

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

Generic Differentiation

Even in the cost-led market for generics, differentiated business models evolve

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

- PMLiVE

Pharma sees European generics export plan as anti-innovation

EFPIA condemns plans - but European Commission says changes would create jobs in Europe

- PMLiVE

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’

- PMLiVE

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Drug is also in phase II trial to treat PTSD patients

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

Life lessons

The recent problems of the generics sector have lessons for research-based companies too

- PMLiVE

Lundbeck partners with 23andMe on first-of-its-kind study

Psychiatry collaboration will combine data from genetics, cognitive tests and online surveys

Eli Lilly HQ

Lilly wins on appeal in Alimta vitamin regimen dispute

UK Supreme Court rules in its favour over Actavis

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

- PMLiVE

Stada opens books to let formal bidding commence

Cinven, Advent International and Bain Capital now have opportunity to revise their bids

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links